Here’s how it works. Ditching single-use plastic bottles isn’t just better for the planet, it’s a smarter way to keep your drinks cool and refreshing all day. The right water bottle can make ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or ...

The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...

GSK plc announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary ...

First up GSK, which got a green light for its PF-1 inhibitor Jemperli (dostarlimab) in combination with chemotherapy as a first-line treatment for all adult patients with primary advanced or ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...